CVRx, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CVRx, Inc. is a commercial-stage medical device company specializing in the development, manufacturing, and commercialization of neuromodulation solutions for patients with cardiovascular diseases. The company’s core product is the Barostim system, an implantable device designed to treat hypertension and heart failure by electrically stimulating the body's natural baroreceptors to regulate blood pressure and cardiovascular function. The product portfolio includes the second-generation Barostim Neo2 implantable pulse generator and associated implantable systems, which provide personalized, non-destructive, and reversible treatment with 100% patient compliance. CVRx distributes its products primarily through a direct sales force in the United States, supported by over 250 active implanting centers and an expanding footprint of 48 sales territories. Founded in 2001 and headquartered in Minneapolis, Minnesota, CVRx operates primarily in the U.S. market with ongoing clinical evaluations and regulatory developments in Europe. The company targets patients with resistant hypertension and heart failure, with a strategic focus on increasing physician and patient awareness, improving access to therapy, and expanding clinical evidence. Recent developments include the launch of their second-generation Barostim Neo2 pulse generator in late 2022, offering enhanced treatment options for heart failure symptoms. In 2024 and 2025, CVRx demonstrated robust commercial growth, increasing U.S. active implanting centers from 208 to 250 and expanding sales territories. CVRx’s latest major strategic activities include raising $12.8 million through at-the-market offerings to support commercial expansion and marketing initiatives focused on salesforce growth and territory development. The company achieved 35% revenue growth in 2024 with forecasted total revenue between $63 million and $65 million for 2025. CVRx continues investment in enhancing its sales and marketing organization to support broader market penetration and patient uptake of Barostim therapy. These operational expansions position CVRx as a leader in implantable neuromodulation therapies for cardiovascular conditions. Overall, CVRx operates in the medical device and healthcare industry, with a clear commercial-stage focus on innovative neuromodulation treatments for cardiovascular diseases. The company maintains a strong emphasis on product innovation, clinical validation, and geographic expansion within the United States, while also exploring opportunities in European markets. CVRx is publicly traded on NASDAQ under the ticker CVRX and maintains proprietary technology centered on baroreceptor activation for improved cardiovascular health outcomes.
CVRx (CVRX) Moves 11.6% Higher: Will This Strength Last?
CVRx, Inc. (CVRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CVRx Announces Chief Financial Officer Transition
CVRx Announces Chief Financial Officer Transition
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
CVRx to Present at the William Blair 46th Annual Growth Stock Conference
CVRx to Present at the William Blair 46th Annual Growth Stock Conference
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX)
CVRx, Inc. (CVRX) Q1 2026 Earnings Call Transcript
CVRx Q1 Earnings Call Highlights
CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates
CVRx Reports First Quarter 2026 Financial and Operating Results
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
CVRx, Inc. Investigated by the Portnoy Law Firm